Citicoline (CDP-Choline)
Multiple RCTs (Spiers et al., 1996; Secades & Lorenzo, 2006) show citicoline improves attention, working memory, and verbal memory in healthy adults and cognitive decline patients. It is one of the most bioavailable choline sources — studies show ~18% greater cognitive improvement compared to choline bitartrate.
Mechanism of action
Citicoline (cytidine 5'-diphosphocholine) is a precursor to both acetylcholine and phosphatidylcholine. It boosts acetylcholine synthesis in the brain — the neurotransmitter central to attention, learning, and memory encoding. It also supports neuronal membrane integrity by replenishing phospholipids.
Clinical evidence summary
Multiple RCTs (Spiers et al., 1996; Secades & Lorenzo, 2006) show citicoline improves attention, working memory, and verbal memory in healthy adults and cognitive decline patients. It is one of the most bioavailable choline sources — studies show ~18% greater cognitive improvement compared to choline bitartrate.
Human effect matrix
Based on human clinical trials only. Animal and in-vitro data excluded.
| Effect | Evidence | Magnitude | Studies |
|---|---|---|---|
| Attention & Focus | strong | Moderate | 8 |
| Working Memory | moderate | Moderate | 6 |
| Brain Energy Metabolism | moderate | Moderate | 4 |
| Neuroprotection | moderate | Large | 5 |
Evidence key: Strong = multiple consistent RCTs · Moderate = smaller/fewer RCTs · Preliminary = early trials or small n · Mixed = conflicting results
Documented benefits
- Attention and focus
- Working memory
- Brain energy metabolism
- Neuroprotection
Side effects & cautions
- Very well tolerated
- Rare: headache at very high doses
- Insomnia if taken late in the day
How to take
Stacking recommendations
Ingredients that pair well with Citicoline (CDP-Choline) and why.
Citicoline handles acute attention and acetylcholine; Bacopa covers long-term memory consolidation. The combination addresses both short-term focus and long-term memory in one stack.
Citicoline provides cognitive activation; L-Theanine takes the edge off overstimulation. Together they produce alert, focused calm without the jitteriness some people experience from citicoline alone.
Complementary timeframes: citicoline works acutely on acetylcholine; Lion's Mane works long-term on NGF. No mechanism overlap — a clean combination.
Frequently asked questions
Citicoline vs choline bitartrate — what is the difference?
Citicoline is significantly superior. It crosses the blood-brain barrier more efficiently and provides two active components: choline (for acetylcholine) and cytidine (which converts to uridine, a brain membrane building block). Choline bitartrate provides choline only and crosses the BBB poorly. Studies show ~18% greater cognitive effect for citicoline at equivalent choline doses.
Should I split my dose?
At 250mg, a single morning dose is fine. At 500mg, some people split it into 250mg morning and 250mg early afternoon for smoother coverage. Avoid any dose after 2–3pm as the mildly activating effect can delay sleep onset.
I got a headache after taking citicoline — is this normal?
A headache from citicoline at standard doses (250–500mg) is unusual and may indicate you are sensitive to cholinergic compounds or already getting significant choline from diet/other supplements. Try reducing to 250mg and do not combine with Alpha-GPC or other choline sources on the same day.
Cognizin vs generic CDP-Choline — does the brand matter?
Cognizin is the most clinically validated form and is tested for purity. Generic CDP-Choline can be fine if sourced from reputable suppliers, but quality varies more. For critical cognitive work, the premium branded form is worth the marginal cost increase.
Top stacks containing Citicoline (CDP-Choline)
Citicoline (CDP-Choline) in the EU
Citicoline holds a specific, dual status under EU food law. The European Commission authorised it as a novel food ingredient in 2014, permitting its use in food supplements up to a fixed daily dose, and in foods for special medical purposes under separate limits, but a 2025 Commission Regulation refused a proposed health claim linking citicoline to memory support after EFSA found the evidence insufficient. In practice this means citicoline is an authorised novel food ingredient for food supplements within set limits, while any health claim about memory on a label would have to appear in the EU list of authorised claims -- and a refused claim is, by definition, not an authorised one.
Novel Food Authorisation and Its Limits
Commission Implementing Decision 2014/423/EU authorised citicoline as a novel food ingredient following an EFSA safety opinion. The Decision states that citicoline "may be placed on the market in the Union as a novel food ingredient in food supplements with a maximum dose of 500 mg per day," and specifies it "shall not be used in foods intended to be consumed by children." This authorisation covers safety and permitted use levels only; it does not extend to any claim about what citicoline does in the body, which is governed separately under the EU's nutrition and health claims rules.
Products in the EU
- Mind Lab Pro9.2/10EU storefrontLocal price: €65/month
- Performance Lab Mind8.6/10EU storefrontLocal price: €55/month
EU food supplement (Reg. 1924/2006 claims)
Is citicoline legally allowed in EU food supplements?
Yes. Commission Implementing Decision 2014/423/EU authorises citicoline as a novel food ingredient in food supplements at a maximum dose of 500 mg per day, and in specific foods for special medical purposes under separate limits. The Decision also states that products containing citicoline are not intended to be consumed by children.
Can an EU product say citicoline supports memory?
Not on the basis of the application decided so far. Commission Regulation (EU) 2025/2223 refused a citicoline memory claim after EFSA concluded a cause-and-effect relationship had not been established. Under Article 10(1) of Regulation (EC) No 1924/2006, health claims are prohibited unless authorised and included in the EU's official list, which this one is not.
EU country guides
Sources: Commission Implementing Decision 2014/423/EU authorising citicoline as a novel food ingredient · Commission Regulation (EU) 2025/2223 refusing a health claim for citicoline and memory function · Regulation (EC) No 1924/2006 on nutrition and health claims made on foods, Article 10(1) · Commission Implementing Decision 2014/423/EU, recital 5 -- food supplements and foods for special medical purposes
Regulatory note
Cognitive-effect language on this page describes ingredient mechanisms studied in clinical trials. Health claims on supplements sold in the EU are governed by Regulation (EC) No 1924/2006; only European Food Safety Authority (EFSA) approved claims may appear on product labelling. This page is editorial, not promotional, and does not constitute medical advice. Consult a qualified healthcare professional before starting any supplement.